###begin article-title 0
###xml 44 51 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
TCF/beta-catenin plays an important role in HCCR-1 oncogene expression
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 9 16 9 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 147 154 147 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 212 217 <span type="species:ncbi:9606">human</span>
Oncogene HCCR-1 functions as a negative regulator of the p53 and contributes to tumorigenesis of various human tissues. However, it is unknown how HCCR-1 contributes to the cellular and biochemical mechanisms of human tumorigenesis.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 799 806 796 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
In this study, we showed how the expression of HCCR-1 is modulated. The luciferase activity assay indicated that the HCCR-1 5'-flanking region at positions -166 to +30 plays an important role in HCCR-1 promoter activity. Computational analysis of this region identified two consensus sequences for the T-cell factor (TCF) located at -26 to -4 (Tcf1) and -136 to -114 (Tcf2). Mutation at the Tcf1 site led to a dramatic decrease in promoter activity. Mobility shift assays (EMSA) revealed that nuclear proteins bind to the Tcf1 site, but not to the Tcf2 site. LiCl, Wnt signal activator by GSK-3beta inhibition, significantly increased reporter activities in wild-type Tcf1-containing constructs, but were without effect in mutant Tcf1-containing constructs in HEK/293 cells. In addition, endogenous HCCR-1 expression was also increased by treatment with GSK-3beta inhibitor, LiCl or AR-A014418 in HEK/293 and K562 cells. Finally, we also observed that the transcription factor, TCF, and its cofactor, beta-catenin, bound to the Tcf1 site.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 170 175 <span type="species:ncbi:9606">human</span>
These findings suggest that the Tcf1 site on the HCCR-1 promoter is a major element regulating HCCR-1 expression and abnormal stimulation of this site may induce various human cancers.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Proto-oncogenes normally help regulate cell growth and differentiation under well-controlled conditions, including mitogenic signal transductions in cells [1,2]. Uncontrolled expression of proto-oncogenes due to mutations or activation of signaling can give rise to a tumor-inducing agent, which is known as an oncogene [2,3]. For more than a decade, there has been a focus on the transcriptional regulation of oncogenes or proto-oncogenes in search of therapeutic clues against cancers which are induced by over-transcription of their oncogenes.
###end p 9
###begin p 10
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 885 887 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 888 890 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Wnt is known as a proto-oncogene and its signaling pathway is a complex network of proteins with roles in embryogenesis [4-6] and cancer [7]. Wnt and its signaling pathway is also involved in normal physiologic processes, including cell polarity [8], axon guidance [9], and stem cell growth factor [10]. Two Wnt pathways have been identified, the canonical and non-canonical pathways. More than 90% of colorectal cancers and other digestive cancers are associated with defects in the canonical Wnt signaling pathway by mutations in APC [11,12], AXIN1 [13], or CTNNB1 [7]. These mutations make it impossible to assist GSK-3beta in phosphorylation and in rapid degradation of beta-catenin through the ubiquitin pathway as a result of accumulation of beta-catenin in the cytoplasm and formation of a complex with TCF in the nucleus, which initiates transcription of the Wnt target genes [14,15].
###end p 10
###begin p 11
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1</italic>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 331 338 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 463 470 463 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 559 566 559 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 122 131 <span type="species:ncbi:10090">nude mice</span>
###xml 380 385 <span type="species:ncbi:9606">human</span>
The human cervical cancer oncogene 1 (HCCR-1) has been identified as a novel oncogene with strong tumorigenic features in nude mice [16]. HCCR-1 is post-translationally localized in the mitochondria, sub-compartmentally in its outer membrane [17,18], and may functionally regulate the p53 tumor-suppressor gene negatively [16,19]. HCCR-1 is also overexpressed in various types of human malignancies, including colorectal cancer [18]. However, it is not known how HCCR-1 expression is modulated. In this study, we characterized the proximal promoter region of HCCR-1 to elucidate the mechanism of expression of the oncoprotein, HCCR-1.
###end p 11
###begin title 12
Results and Discussion
###end title 12
###begin title 13
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human HCCR-1 5'-flanking sequences
###end title 13
###begin p 14
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Previous work has identified the initiation site for transcription and the promoter region of the HCCR-1 gene [20]. Computational analysis has shown that the HCCR-1 promoter contains a TATA box, a CAAT box, and the putative DNA binding sites for various transcriptional factors [20].
###end p 14
###begin p 15
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 528 535 528 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 621 628 621 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 805 812 805 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1132 1139 1132 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 1199 1206 1199 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 799 804 <span type="species:ncbi:9606">human</span>
To characterize the HCCR-1 promoter, fragments from positions -980, -538, -474, and -166 to position +30 (end of the 5'UTR region) and position -980 to position -510 were cloned into upstream of a luciferase reporter gene and assayed for their transcriptional activities in either chronic myelogenous leukemia K562, HEK/293, or lung cancer A549 cells (Figure 1A). The activities from all the constructs tested were high in the K562, but weak in HEK/293 and nearly undetectable in A549 cells, indicating that the activity of the HCCR-1 promoter is constitutively enhanced in K562 cells. Northern blot analysis showed that HCCR-1 expression is high in K562 and weak in A549 cells, which is consistent with the present work [16]. Transient transfection of a reporter fragment containing -474 to +30 of human HCCR-1 (referred to hereafter as 'pGL3-474~+30') had 97.5 times higher promoter activity than the reporter gene alone (pGL3-Basic) in K562 cells (Figure 1A). However, the shortest fragment (pGL-166~+30) had high promoter activity, while the deleted mutant (pGL-980~-510) had very weak activity (Figure 1A), suggesting that the HCCR-1 promoter region from -166 to +30 plays an important role in HCCR-1 gene expression.
###end p 15
###begin p 16
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of the truncated <italic>HCCR-1 </italic>promoter in K562, HEK/293, or A549 cells</bold>
###xml 130 137 130 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 316 317 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 452 460 452 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">renilla </italic>
###xml 525 533 525 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">renilla </italic>
###xml 762 764 762 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 401 404 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 616 619 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Expression of the truncated HCCR-1 promoter in K562, HEK/293, or A549 cells. The DNA constructs containing various lengths of the HCCR-1 promoter region were cloned into upstream of the firefly luciferase (LUC) reporter gene. Each luciferase reporter construct shown in the diagram was co-transfected in K562 (A and B; filled bars), HEK293 (A; open bars), and A549 (A; shadow bars) cells with the pRL-CMV normalizing reporter plasmid encoding with the renilla (REN) gene. The horizontal axis shows the ratio of luciferase to renilla activity normalized by LUC/REN (= 100%) displayed by cells co-transfected with pRL-CMV and pGL3-control. We designated each recombinant vector as pGL3X~Y, where X is the first base and Y the last base of each truncated promoter (n > 5 per construct).
###end p 16
###begin p 17
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 627 634 627 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 775 782 775 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
To further characterize the HCCR-1 promoter region from -166 to 30, promoter fragments from positions -118 and -75 to position +30 and from positions -474 to position -52 were cloned into upstream of a luciferase reporter gene and assayed for their transcriptional activity in K562 cells (Figure 1B). The fragment (pGL-166~+30) had 1.85 times higher promoter activity than pGL-75~+30 and 1.53 times higher promoter activity than pGL3-118~+30 in K562 cells. However, this activity was dramatically reduced by the deleted mutant (pGL-474~-52) which was removed at positions -52 to +30 (Figure 1B). These results suggest that the HCCR-1 5'-flanking region at positions -52 to +30 is required for HCCR-1 promoter activity and this region may possess important elements enhancing HCCR-1 transcription.
###end p 17
###begin title 18
The Tcf1 Site is involved in the activation of the HCCR-1 promoter
###end title 18
###begin p 19
###xml 18 20 18 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 214 221 214 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 732 739 732 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
The MatInspector [21] identified two T-cell factor (TCF) binding sites, designated as Tcf1 and Tcf2 in Figure 2[15,22,23] and one c-myb site designated as My in Figure 2[24,25] within the -166 to +30 region of the HCCR-1 promoter. To investigate the role of these elements in the modulation of transcriptional activity, each was inactivated by site-directed mutagenesis and cloned into upstream of a luciferase reporter gene. Each mutated construct (pGL3-mTcf1, -mTcf2, and -mMyb) was transiently expressed in K562 cells and the luciferase activity was measured. Mutation of the Tcf2 or c-myb-binding sites did not significantly modify luciferase expression (Figure 2). In contrast, mutation of the Tcf1 site significantly affected HCCR-1 promoter activity. We thus focused on the Tcf1 site for further investigations.
###end p 19
###begin p 20
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mutational analysis of the <italic>HCCR-1 </italic>promoter</bold>
###xml 123 130 123 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 428 436 428 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">renilla </italic>
###xml 547 549 547 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 364 367 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 525 528 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Mutational analysis of the HCCR-1 promoter. The diagrams depict locations of the predicted transcriptional elements in the HCCR-1 promoter. When mutated, the diagrams are indicated by a cross. "Tcf" and "My" indicate the consensus sequences for the TCF and C-Myb elements, respectively. Each luciferase reporter construct was co-transfected in K562 cells with pRL-CMV. The horizontal axis shows the ratio of luciferase (LUC) to renilla (REN) activity normalized by LUC/REN (= 100%) displayed by cells co-transfected with pRL-CMV and pGL3-control (n > 4 per construct).
###end p 20
###begin title 21
Nuclear proteins extracted from K562 cells recognize the sequences of the Tcf1 site
###end title 21
###begin p 22
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 222 229 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1008 1015 1008 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
To confirm that Tcf1 plays a role in HCCR-1 promoter activation, we then performed an electrophoretic mobility shift assay (EMSA) in the K562 nuclear extracts by using double-stranded oligonucleotides harboring either the HCCR-1 wild-type sequences, designated as Tcf1 (-26~-4), Tcf2 (-136~-114), or a mutated Tcf1 sequence (mTcf1). Two retarded bands were obtained with the radiolabeled probe carried the wild-type Tcf1 site, but no band in the labeled probe carrying the Tcf2 site (Figure 3A). The band was abolished by pre-incubation with a 10 times molar excess of cold Tcf1 probe, but not abolished with cold probes that carried Tcf2 or Ery (erythroid krueppel like factor; -294~-272) probes, which were used as a non-competitor (Figure 3A). The band also disappeared when using the probe encoding the mutated Tcf1 site, mTcf1 (Figure 3B), suggesting that proteins included in the K562 nuclear extracts recognized and bound to the wild-type specific sequences which are situated in the Tcf1 site on the HCCR-1 promoter.
###end p 22
###begin p 23
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DNA-binding activity at the Tcf1 site</bold>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
DNA-binding activity at the Tcf1 site. EMSA were performed using K562 nuclear extracts and dsDNA harboring either a consensus site for HCCR-1 wild-type Tcf1, Tcf2 element (A), and a mutated sequence mTcf1 (B). To show the specificity of the bands, 10 times molar excess of cold double-stranded oligonucleotide carrying the consensus Tcf1 and Tcf2 sites was used for competition or Ery for non-competition. B1 indicates the DNA-protein complex with probe Tcf1 and B2 indicates less specific DNA-protein complex. The presence or absence of a component in the assay is indicated by a "+" or "-", respectively.
###end p 23
###begin p 24
###xml 19 21 19 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 252 259 252 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 385 392 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 688 695 688 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 794 801 794 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 71 76 <span type="species:ncbi:9606">human</span>
As shown in Figure 1B, the reporter fragment containing -166 to +30 of human HCCR-1 was significantly increased in comparison with the fragment containing -118 to +30. However, EMSA assays revealed no major band when the radiolabeled probe carried the HCCR-1 wild-type Tcf2 sequences (Figure 3A), suggesting that there is another element downstream from the Tcf2 region to -166 of the HCCR-1 promoter region. We have searched this region, and detected three shifted bands by the EMSA method (unpublished data). These bands disappeared in the presence of a cold competitor and were not with the non-competitor. Site-directed mutagenesis work also revealed that the region is important for HCCR-1 expression, but further study is required to gain better insight into the biologic significance in HCCR-1 expression.
###end p 24
###begin title 25
HCCR-1 promoter was activated by LiCl, an inhibitor of GSK-3beta
###end title 25
###begin p 26
###xml 78 80 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 81 83 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 191 198 185 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 219 221 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 344 346 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 552 554 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
Lithium has been shown to stabilize beta-catenin via inhibition of GSK-3beta [14,26], and as a result, activates TCF. To examine whether TCF activation by treatment with 5 mM LiCl stimulated HCCR-1 promoter expression [26], we performed reporter assays with deletion constructs containing Tcf1 or both Tcf1 and Tcf2 sites in K562 cells (Figure 4A). LiCl treatment increased reporter activities 1.7- to 2.25-fold with constructs pGL3-75~+30,-118~+30 which contain the Tcf1 site, and 1.8-fold with pGL3-166~+30 containing the Tcf1 and Tcf2 sites (Figure 4A).
###end p 26
###begin p 27
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 0 82 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TheTcf1 site on the <italic>HCCR-1 </italic>promoter was sensitive to the GSK-3&#946; inhibitor, LiCl</bold>
###xml 110 111 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 136 137 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 146 153 143 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 345 347 342 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 211 214 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
TheTcf1 site on the HCCR-1 promoter was sensitive to the GSK-3beta inhibitor, LiCl. The truncated constructs (A) or mutated constructs (B) of the HCCR-1 promoter region were transfected into K562 cells with pRL-CMV as an internal control. Cells were then treated with or without 5 mM LiCl for 24 hours and subjected to dual luciferase analysis (n > 4 per construct).
###end p 27
###begin p 28
###xml 179 186 179 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 529 536 529 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
Another reporter assay with constructs pGL3-mTcf1 or -mTcf2, which are mutated at the Tcf1 or Tcf2 sites within the -166 to +30 region, was performed to verify Tcf1 involvment in HCCR-1 promoter activity. pGL3-mTcf1 markedly attenuated the induction of HCCR-1 promoter activity by treatment with LiCl in comparison with wild-type pGL3-166~+30, but there was no significant change at the mutation of the Tcf2 site (pGL3-mTcf2; Figure 4B). These results suggest that Tcf1 appears to be important for LiCl-induced activation of the HCCR-1 promoter.
###end p 28
###begin title 29
Endogenous HCCR-1 transcripts were increased by GSK-3beta inhibitors
###end title 29
###begin p 30
###xml 89 96 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 211 213 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 259 261 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 352 354 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 431 438 427 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 601 603 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 608 610 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 631 638 626 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 768 770 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 775 777 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 825 832 819 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
To verify activation induced by stimulation of the Wnt/beta-catenin signal on endogenous HCCR-1 mRNA expression, K562 or HEK293 cells were treated with various concentration of LiCl (0, 1, 2, 5, 10, and 20 mM) [26] or AR-A014418 (0, 1, 2, 5, 10, and 20 muM) [27] for 24 h and the levels of expression were analyzed by real-time PCR. As shown in Figure 5A, the stimulated K562 cells (2, 5 or 10 mM) were increased the expression of HCCR-1 compared with unstimulated cells (0 mM), and the expression was increased 13.7-fold in the cells treated with 5 mM LiCl and 9.3-fold with 5 muM AR-A014418 (Figure 5A and 5B). The expression of HCCR-1 mRNA was increased 6.6-fold in the HEK/293 cells treated with 5 mM LiCl and 6.26-fold in same cells with 5 muM AR-A014418 (Figure 5C and 5D). These results suggest that the expression of HCCR-1 is modulated by the activation of transcription factor, TCF, induced by beta-catenin stability.
###end p 30
###begin p 31
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 0 131 0 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Endogenous expression of <italic>HCCR-1 </italic>on activated Wnt/&#946;-catenin signal by treatment with the GSK-3&#946; inhibitors, LiCl or AR-A014418</bold>
###xml 169 176 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A and B</italic>
###xml 191 198 185 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C and D</italic>
###xml 261 268 255 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A and C</italic>
###xml 285 292 279 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B and D</italic>
###xml 486 488 474 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 421 426 <span type="species:ncbi:9606">human</span>
Endogenous expression of HCCR-1 on activated Wnt/beta-catenin signal by treatment with the GSK-3beta inhibitors, LiCl or AR-A014418. Total RNAs were prepared from K562 (A and B) and HEK/293 (C and D) cells which were treated with various concentration of LiCl (A and C) or AR-A014418 (B and D) for 24 hours in respectively. Five mug of total RNAs were used for cDNA synthesis and subjected to real-time PCR analysis with human specific primers for HCCR-1 and beta-actin (mean +/- S.D., n = 3).
###end p 31
###begin title 32
TCF and beta-catenin are bound to the Tcf1 site on the HCCR-1 promoter
###end title 32
###begin p 33
###xml 40 47 40 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 211 218 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 344 345 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 387 389 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 420 422 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 645 652 636 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
We have shown that the Tcf1 site on the HCCR-1 proximal 5'-flanking region regulates endogenous HCCR-1 expression. We next investigated whether TCF and its cofactor (beta-catenin) could physically bind with the HCCR-1 promoter using a super-shift assay with the radiolabeled oligo Tcf1 probes and nuclear extracts from K562. As shown in Figure 6, incubation with either anti-TCF (Figure 6A) or anti-beta-catenin (Figure 6B) antibodies resulted in a super shift of the DNA-protein complexes, whereas incubation with a nonspecific IgG did not shift the DNA-protein complexes, confirming that TCF and beta-catenin are bound to the Tcf1 site on the HCCR-1 promoter.
###end p 33
###begin p 34
###xml 56 63 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 0 78 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TCF and &#946;-catenin bound with the Tcf1 element on the <italic>HCCR-1 </italic>promoter region</bold>
###xml 212 213 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 232 233 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
TCF and beta-catenin bound with the Tcf1 element on the HCCR-1 promoter region. Super-shift assays using K562 nuclear lysates were tested with labeled oligo probes Tcf1 and 0.4 mug antibodies against either TCF (A) or beta-catenin (B). Anti-IgG indicate non-specific antibody for control. Arrows indicate super-shifted bands.
###end p 34
###begin p 35
###xml 153 154 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 155 157 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 158 160 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 364 366 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 473 475 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 492 499 483 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 581 583 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 622 629 613 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 707 713 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1</italic>
###xml 729 736 720 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
###xml 822 827 <span type="species:ncbi:9606">human</span>
Wnt signaling is constitutively active in the majority of human colorectal cancers by mutations which lead to increased beta-catenin protein expression [7,11-13], resulting in nuclear accumulation of beta-catenin, which subsequently complexes with TCF transcription factors and activation of downstream beta-catenin/TCF target genes, including Bcl-2 family genes [28]. HCCR-1 is also overexpressed in colorectal cancer and interacts with DP1 on the mitochondrial membrane [18]. Overexpressed HCCR-1 may contribute to the cellular and biochemical mechanisms of human tumorigenesis [18]. In this study, we characterized the HCCR-1 promoter and elucidated the mechanism of expression of the strong oncoprotein HCCR-1. We found that HCCR-1 expression is directly modulated by TCF/beta-catenin signaling and may play a role in human cancer.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 137 144 137 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 215 222 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 372 379 372 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 547 554 547 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 680 687 677 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 850 857 844 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 932 939 926 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 980 987 974 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
HCCR-1 has been isolated as an oncogene candidate and is overexpressed in various cancers [16,18,19,29]. To understand the modulation of HCCR-1 expression, several deleted mutants of the proximal promoter region of HCCR-1 were constructed. Reporter gene assays in K562 cells demonstrated that the proximal promoter region at nucleotides -166 to +30 have a pivotal role in HCCR-1 transcription. Mutagenesis of the Tcf1 site significantly decreased the reporter activity compared with its wild-type. Our data also indicate that the transcription of HCCR-1 is activated by treatment with LiCl, the reagent sensitive to GSK-3beta. Site-directed mutagenesis on the Tcf1 site makes the HCCR-1 promoter activity insensitive to the stimulation of beta-catenin/TCF signaling by LiCl. In addition, stimulation with LiCl or AR-A014418 also increased endogenous HCCR-1 expression in K562 and HEK/293 cells, suggesting that the Tcf1 site on the HCCR-1 proximal promoter is a major element for HCCR-1 expression. Finally, we also observed that the transcription factor, TCF, and its cofactor (beta-catenin) are indeed bound to the Tcf1 site.
###end p 37
###begin title 38
Methods
###end title 38
###begin title 39
Cell culture
###end title 39
###begin p 40
###xml 276 278 270 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 420 422 408 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic kidney (HEK) 293 (ATCC CRL-1573), K562 chronic myelogenous leukemia (ATCC CCL-243), and A549 lung cancer (ATCC CCL-185) cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The HEK/293 cells were maintained at 37degreesC and 5% CO2 in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% FBS and 1% penstrep (Gibco). K562 and A549 were maintained at 37degreesC in 5% CO2 in RPMI (Gibco) containing 10% FBS and 1% penstrep.
###end p 40
###begin title 41
Isolation of the promoter region and DNA transfection
###end title 41
###begin p 42
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfu </italic>
###xml 173 180 173 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 512 513 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 604 605 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1000 1003 970 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 1009 1012 979 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 141 153 <span type="species:ncbi:10710">lambda phage</span>
Eight DNA fragments from the HCCR-1 promoter region (Figures 1A and 1B) were synthesized using a Pfu DNA polymerase (MBI Fermentas, MD). The lambda phage DNA containing the HCCR-1 genomic DNA was amplified using the primers G1-R and G1-F for pGL3-75~+30, G1-R and G2-F for pGL3-118~+30, G1-R and G3-F for pGL3-166~+30, G1-R and G4-F for pGL3-474~+30, G2-R and G4-F for pGL3-474~-52, G1-R and G5-F for pGL3-538~+30, G1-R and G6-F for pGL3-980~+30, and the primers G3-R and G6-F for pGL3-980~-510 (Additional file 1: Table S1). The primer sequences used in these PCR reactions are shown in Additional file 1: Table S1 (GenoTech, Daejeon, Korea). The PCR cycling parameters were as follows: initial denaturation at 94degreesC for 2 min; 30 cycles of 30 s at 94degreesC for denaturation; 30 s at 55degreesC for primer annealing; 1 min at 72degreesC for extension; and final extension at 72degreesC for 10 min. The PCR products were subcloned into the pGL3-Basic vector (Promega, Madison, WI, USA) at the KpnI and XhoI sites and confirmed by sequencing (GenoTech). All plasmids and recombinant plasmids were prepared using Qiagen columns (Qiagen Inc, Valencia, CA, USA).
###end p 42
###begin p 43
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
For DNA transfection, K562, HEK/293, and A549 cells were co-transfected with 200 ng pGL3-basic vector containing the HCCR-1 promoter regions and 40 ng pCMV-RL, as an internal standard, using 3 mul Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol.
###end p 43
###begin title 44
Luciferase (LUC) reporter assay
###end title 44
###begin p 45
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HCCR-1 </italic>
###xml 393 401 393 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
###xml 714 722 714 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla </italic>
K562, HEK/293, and A549 cells were co-transfected with the pGL3-basic vector containing various HCCR-1 promoter regions and pCMV-RL. To investigate the effect of the Wnt-signal pathway on HCCR-1 expression, cells were treated with 5 mM LiCl (Sigma-Aldrich Corporation, St. Louis, MO, USA) for 24 h, then harvested. After lysis, the cell suspensions were centrifuged at 12,000 x g. Firefly and Renilla luciferase activities of cell lysates were measured according to the manufacturer's instructions for the Dual Luciferase Assay System (Promega) in a Turner TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). The relative firefly luciferase activity was calculated by normalizing transfection efficiency to Renilla luciferase activity for each cell type. An error bar is used to show the SD derived from more than four independent experiments.
###end p 45
###begin title 46
Mutagenesis
###end title 46
###begin p 47
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Pairs of complimentary oligonucleotides containing the desired mutations were synthesized (GenoTech). Mutated plasmids were obtained using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The mutagenesis reaction was performed following the manufacturer's protocol using the pGL3-166~+30 plasmid for pGL3-mTcf1, pGL3-mTcf2, and pGL3-mMyb as a template. Mutagenesis products were obtained as follows: pGL3-mTcf1 using primers mT1-F and mT1-R; pGL3-mTcf2 using mT2-F and mT2-R; and pGL3-mMyb using mMyb-F and mMyb-R (Additional file 1: Table S2). The nucleotide sequence of each construct was verified by automated sequencing (GenoTech). All primer sequences used in mutagenesis are shown in Additional file 1: Table S2.
###end p 47
###begin title 48
Nuclear protein extraction
###end title 48
###begin p 49
###xml 193 195 193 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 343 344 342 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 793 794 784 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Nuclear extracts were prepared from K562 cells according to the manufacturer's instructions using a nuclear extraction kit (Sigma-Aldrich Corporation), with minor modifications. Briefly, 1 x 107 cells were washed twice with ice-cold phosphate-buffered saline and resuspended in 500 mul hypotonic lysis buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 1 mM dithiothreitol, and protease inhibitor cocktail) for K562 and left on ice for 15 min. Cells were centrifuged for 5 min at 420 x g and resuspended again in 200 mul of the hypotonic lysis buffer. After the lysates were passed 5 times through a 27-gauge needle, nuclei were recovered by centrifugation at 10,000 x g for 20 min at 4degreesC. The nuclei were resuspended in 80 mul of extraction buffer (60 mM HEPES [pH 7.9], 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 25% glycerol, 1 mM dithiothreitol, and protease inhibitor cocktail) and incubated on ice for 30 min. The mixture was centrifuged at 20,000 x g at 4degreesC for 5 min, and the supernatant (the nuclear extract) was collected and stored at -70degreesC until use. Protein concentrations of the nuclear extract were determined by the Bradford assay.
###end p 49
###begin title 50
Electrophoretic mobility shift assay (EMSA)
###end title 50
###begin p 51
###xml 264 265 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 391 393 386 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 629 631 624 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
EMSA was performed using 3.0 mug of nuclear extracts prepared from K562 cell lines. Double-stranded oligonucleotide probes (Tcf1 for primers emT1-F and emT1-R, Tcf2 for emT2-F and emT2-R, Ery for emEry-F and emEry-R, and mTcf1 for mT1-F and mT1-R; Additional file 1: Table S2) were generated by annealing an antisense strand to its complementary matched sense strand and labeled with [gamma-32P]ATP (3,000 Ci/mmol [10 mCi/ml]; NEN Life Science products) and T4 polynucleotide kinase (Takara). The Gel Shift Assay System kit (Promega) was used for the binding reaction, which was performed as recommended by the manufacturer. The 32P-labeled probes were added to the nuclear extract and reacted for 20 min.
###end p 51
###begin p 52
###xml 273 275 269 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 688 689 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 51 55 <span type="species:ncbi:9925">goat</span>
###xml 61 67 <span type="species:ncbi:9986">rabbit</span>
###xml 75 81 <span type="species:ncbi:9986">rabbit</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 122 128 <span type="species:ncbi:9986">rabbit</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
For super-shift analysis, 0.4 mug of a nonspecific goat anti-rabbit IgG, a rabbit anti-human TCF polyclonal antibody or a rabbit anti-human beta-catenin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to the nuclear extract mixture containing 32P-labeled probes and reacted for 20 min. The reaction mixtures were resolved on a 6% non-denaturing polyacrylamide gel in 0.5 times Tris borate-EDTA buffer at 250 V for 30 min. The gel was dried and exposed to an x-ray film (Kodak) at -70degreesC for ~6 h. After that, the bands were visualized by autoradiography. The putative consensus oligonucleotides and mutant oligonucleotides are listed in Additional file 1: Table S2.
###end p 52
###begin title 53
Real-time PCR and Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
###end title 53
###begin p 54
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 225 227 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 531 532 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 777 778 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
K562 and HEK/293 cells were incubated with serum-free media for 24 h and then treated with LiCl (0, 1, 2, 5, 10, or 20 mM; Sigma-Aldrich Corporation) [26] or AR-A014418 (0, 1, 2, 5, 10, or 20 muM; Sigma-Aldrich Corporation) [27] for 24 h and harvested. Total RNAs were prepared using a TRIZOL Reagent (Invitrogen) according to the manufacturer's recommendation. 3~5 mug of total RNA were reverse-transcribed using RevertAidtrade mark M-MuLV reverse transcriptase (MBI Fermentas, USA), 0.2 mug random primer (Invitrogen, USA), 1 mM dNTPs, and the supplied buffer. Each group of the first strand cDNAs was amplified using Power SYBR Green PCR master mix (Abioscience, UK) with the primer pairs RT-F and RT-R for the HCCR-1 gene or Act-F and Act-R for beta-actin (Additional file 1: Table S1). The real-time PCR cycling parameters were as follows: initial denaturation at 95degreesC for 10 min; 40 cycles of 15 sec at 95degreesC for denaturation, 1 min at 60degreesC for primer annealing and extension. An error bar is used to show the S.D. derived from three independent experiments.
###end p 54
###begin title 55
Abbreviations
###end title 55
###begin p 56
###xml 290 297 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">renilla</italic>
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
HCCR-1: human cervical cancer oncogene 1; TCF: T-cell factor; EMSA: electrophoretic mobility shift assay; GSK-3beta: Glycogen synthase kinase-3beta; K562: chronic myelogenous leukemia 562; HEK/293: human embryonic kidney 293; DMEM: Dulbecco's modified Eagle's medium; LUC: luciferase; RAN: renilla; UTR: untranslated region; DP1: deleted in polyposis 1.
###end p 56
###begin title 57
Authors' contributions
###end title 57
###begin p 58
JWK and SHK designed the studies, analyzed data and wrote the manuscript. GC, MK, SH, HKK and SK performed the luciferase activity assay, computational analysis, mutation experiment, and EMSA assay. All authors contributed to editing the manuscript.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
Additional file 1
###end title 60
###begin p 61
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tables</bold>
Tables. Table S1 and Table S2.
###end p 61
###begin p 62
Click here for file
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
This work was supported by the grant from the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) (M10870050005-08N7005-00510), the grant from the Korea Research Foundation Grant (KRF-2002-005-E00013) and funded by the Korean Government (MOEHRD, Basic Research Promotion Fund; KRF-2005-206-E00004).
###end p 64
###begin article-title 65
Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta
###end article-title 65
###begin article-title 66
Oncogenes
###end article-title 66
###begin article-title 67
Tumor progression and metastasis
###end article-title 67
###begin article-title 68
###xml 51 61 <span type="species:ncbi:7227">Drosophila</span>
Mutations affecting segment number and polarity in Drosophila
###end article-title 68
###begin article-title 69
A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling
###end article-title 69
###begin article-title 70
Repression of Teashirt marks the initiation of wing development
###end article-title 70
###begin article-title 71
Caught up in a Wnt storm: Wnt signaling in cancer
###end article-title 71
###begin article-title 72
Planar polarity from flies to vertebrates
###end article-title 72
###begin article-title 73
The Wnt receptor Ryk is required for Wnt5a-mediated axon guidance on the contralateral side of the corpus callosum
###end article-title 73
###begin article-title 74
Wnt proteins are lipid-modified and can act as stem cell growth factors
###end article-title 74
###begin article-title 75
Wnt breakers in colon cancer
###end article-title 75
###begin article-title 76
Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC
###end article-title 76
###begin article-title 77
Colorectal cancer and genetic alterations in the Wnt pathway
###end article-title 77
###begin article-title 78
The role of the Wnt signalling pathway in colorectal tumorigenesis
###end article-title 78
###begin article-title 79
Shutting down Wnt signal-activated cancer
###end article-title 79
###begin article-title 80
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 93 98 <span type="species:ncbi:9606">human</span>
Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization
###end article-title 80
###begin article-title 81
HCCR-1, a novel oncogene, encodes a mitochondrial outer membrane protein and suppresses the UVC-induced apoptosis
###end article-title 81
###begin article-title 82
HCCR-1-interacting molecule "deleted in polyposis 1" plays a tumor-suppressor role in colon carcinogenesis
###end article-title 82
###begin article-title 83
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 94 109 <span type="species:ncbi:10090">transgenic mice</span>
Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice
###end article-title 83
###begin article-title 84
The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression
###end article-title 84
###begin article-title 85
MatInspector and beyond: promoter analysis based on transcription factor binding sites
###end article-title 85
###begin article-title 86
Transgenic Wnt/TCF pathway reporters: all you need is Lef?
###end article-title 86
###begin article-title 87
Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin
###end article-title 87
###begin article-title 88
The myb oncogene
###end article-title 88
###begin article-title 89
###xml 30 35 <span type="species:ncbi:9606">human</span>
Targeting c-Myb expression in human disease
###end article-title 89
###begin article-title 90
Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling
###end article-title 90
###begin article-title 91
Maintenance of constitutive IkB kinase activity by glycogen synthase kinase-3a/b in pancreatic cancer
###end article-title 91
###begin article-title 92
Inhibition of apoptosis during development of colorectal cancer
###end article-title 92
###begin article-title 93
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma
###end article-title 93

